<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5001">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02085902</url>
  </required_header>
  <id_info>
    <org_study_id>CHD 079-13</org_study_id>
    <nct_id>NCT02085902</nct_id>
  </id_info>
  <brief_title>Does the Use of Ropivacaine Facilitates Cholecystectomy by Laparoscopy in Ambulatory Surgery?</brief_title>
  <acronym>VesiRop</acronym>
  <official_title>Does the Use of Ropivacaine Facilitates Cholecystectomy by Laparoscopy in Ambulatory Surgery?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the recommendations of the French Society of Digestive Surgery 2010, cholecystectomy
      can be performed as outpatient surgery. This approach is difficult in many centers because
      of post operative pain and nausea/vomiting.

      The use of postoperative morphine may be responsible for the state of nausea. The use of
      ropivacaine allows a reduction of the morphine consumption and thus may allow the patient to
      have their surgery as an outpatient.

      Currently, ropivacaine is used randomly during the investigators surgeries. Initially, it
      was used for the infiltration holes trocar.  In recent years, ropivacaine is used for the
      reduction of intra-abdominal postoperative pain. Its use is made of parietal surgery (
      hernia ) in cholecystectomy and colonic surgery. This mode of administration is allowed to
      view the many publications made ​​on this subject. Its use in the investigators daily
      surgery, however, has not been evaluated in ambulatory surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Time to discharge patient after surgery</measure>
    <time_frame>6 hours postoperative</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cholecystectomy</condition>
  <condition>Laparoscopy</condition>
  <arm_group>
    <arm_group_label>standard anesthesia</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>standard anesthesia with ropivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ropivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <arm_group_label>standard anesthesia with ropivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Programmed Cholecystectomy

          -  Laparoscopy

          -  Man and woman

          -  ≥ 18 and &lt;70 years

          -  ASA 1 or 2

          -  Not living alone

          -  Patient living within 50 km of CHD Vendee (site of La Roche sur Yon)

          -  Signature of Informed Consent Form

        Exclusion Criteria:

          -  Cholecystectomy emergency

          -  Patient minor

          -  Pregnant woman (pregnancy test) or during breastfeeding

          -  Patient older than 70 years

          -  Conversion to laparotomy

          -  Patient anticoagulant curative dose

          -  Living alone

          -  Patient addict

          -  Peptic Ulcer

          -  Refusal to enter the protocol

          -  Chronic requiring analgesics long-term

          -  Immunosuppression

          -  Treatment with corticosteroids.

          -  Discovery intraoperative calculation in the bile duct

          -  Contraindication to ropivacaine (see cons-indications to ropivacaine)

          -  Hypersensitivity to study treatment or concomitant medications anesthesia

          -  Cardiac or unbalanced epileptic patients (due to the risk of cardiovascular and
             neurological local anesthetics)

          -  Patients ASA ≥ 3

          -  Patient &lt;50 kg
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emeric ABET, Dr</last_name>
    <role>Study Director</role>
    <affiliation>CHD Vendée La Roche sur Yon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lucie AUZANNEAU</last_name>
    <email>lucie.auzanneau@chd-vendee.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre hospitalier départemental Vendée</name>
      <address>
        <city>La Roche sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie AUZANNEAU</last_name>
      <email>lucie.auzanneau@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Emeric ABET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>March 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
